Sponsored

Chimeric Therapeutics (ASX:CHM) doses first patient in cell therapy trial

August 27, 2024 10:44 PM EDT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Chimeric Therapeutics (ASX:CHM) doses first patient in cell therapy trial
Image source: Shutterstock

Highlights

  • The first patient in the Phase 1/2 clinical trial of CHM CDH17 has been dosed at the Sarah Cannon Research Institute in Tennessee.
  • Patient recruitment for this first-in-human clinical trial is currently underway at cancer centers across the United States.
  • Phase 1 of the trial aims to enrol 15 patients.

Chimeric Therapeutics Limited (ASX:CHM) has reached a significant milestone in its Phase 1/2 clinical trial of CDH17-directed CAR-T cell therapy with the dosing of the first patient at Sarah Cannon Research Institute in Tennessee, the United States.

CHM CDH17 is a third generation CAR T cell therapy targeting CDH17, a cancer marker associated with poor prognosis and metastasis in gastrointestinal tumours. Recruitment for this two-stage, first-in-human clinical trial is progressing at cancer centres across the United States.

Data source: Company update

Phase 1 of this trial is anticipated to enrol 15 patients and will include dose selection and expansion with indication-specific Phase 2 cohorts.

 Data source: Company update

CHM shares trade higher

CHM shares traded at AU$0.017 apiece, up more than 6%, at the time of writing on 28 August 2024.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Canadian AI All-Stars: Unveiling the Top Stocks for 2024

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.